
北美转移癌药物市场预测至 2028 年 - COVID-19 影响和按癌症类型(乳腺癌、肺癌、肝癌、血液癌、脑癌、前列腺癌、胰腺癌等)、给药途径进行的区域分析(静脉内和肌肉内)、药物类别(HER2 抑制剂、免疫检查点抑制剂、PARP 抑制剂、激酶抑制剂等)、产品(品牌药、仿制药和生物仿制药)和最终用户(医院、专科诊所等)
No. of Pages: 160 | Report Code: BMIRE00025361 | Category: Life Sciences
No. of Pages: 160 | Report Code: BMIRE00025361 | Category: Life Sciences
一些最常见的癌症类型包括肺癌、乳腺癌、结肠癌、直肠癌和前列腺癌。每年约有 400,000 名儿童患有这种疾病。 2018 年,致癌感染,包括幽门螺杆菌、乙型肝炎病毒、人乳头瘤病毒 (HPV)、丙型肝炎病毒和 Epstein-Barr 病毒,导致了 2018 年该地区约 13% 的癌症病例。国际癌症研究机构 (IARC) 预计,到 2040 年,全球新发癌症病例和癌症相关死亡人数将从 2018 年的 1640 万增长约 1.6-1.7 倍,达到 2950 万。临床肿瘤学会预计,2021 年,美国约有 290,560 人(287,850 名女性和 2,710 名男性)被诊断患有浸润性乳腺癌。女性乳腺癌现已超过肺癌,成为全球最常诊断的癌症。 2020 年,约 2,261,419 名女性被诊断出患有乳腺癌。
过去几十年来美国记录的所有癌症观察结果表明,转移性癌症占乳腺癌患者的 90%。每年所有癌症死亡。这些数字促使医生和研究人员寻找新的方法来治疗转移,当癌症扩散到其原发点之外时就会发生转移。在美国,6% 的女性在首次诊断时就被诊断出患有转移性乳腺癌。癌症和转移性癌症患病率的上升正在推动转移性癌症药物市场的增长。
随着新功能和技术的发展,供应商可以吸引新客户并扩大他们在新兴市场的足迹。这一因素可能会推动未来几年转移性癌症药物市场的增长。预计该市场在预测期内将以良好的复合年增长率增长。
北美转移性癌症药物市场细分
北美转移性癌症药物市场根据癌症类型、途径进行细分管理、药物类别、产品和最终用户。根据癌症类型,市场分为乳腺癌、肺癌、肝癌、血液癌、脑癌、前列腺癌、胰腺癌等。根据给药途径,市场分为静脉注射和肌肉注射。 根据药物类别,北美转移癌药物市场分为 HER2 抑制剂、免疫检查点抑制剂、parp
抑制剂、激酶抑制剂和其他的。根据产品,市场分为品牌药、仿制药和生物仿制药。根据最终用户,市场分为医院、专科诊所等。按国家/地区划分,北美转移性癌症药物市场分为美国、墨西哥和加拿大。
北美转移性癌症药物市场癌症药物市场 – 提及的公司
AbbVie Inc.;安进公司;百时美施贵宝公司; F. 霍夫曼拉罗什有限公司;诺华公司;阿斯利康;礼来公司;默克公司;辉瑞公司(Arena Pharmaceutical GmbH);和强生服务公司是北美转移性癌症药物市场的领先公司之一。
Strategic insights for North America Metastatic Cancer Drugs involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 21,414.73 Million |
Market Size by 2028 | US$ 27,989.14 Million |
Global CAGR (2021 - 2028) | 3.9% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 癌症类型
|
Regions and Countries Covered | 北美
|
Market leaders and key company profiles |
The regional scope of North America Metastatic Cancer Drugs refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Metastatic Cancer Drugs Market is valued at US$ 21,414.73 Million in 2021, it is projected to reach US$ 27,989.14 Million by 2028.
As per our report North America Metastatic Cancer Drugs Market, the market size is valued at US$ 21,414.73 Million in 2021, projecting it to reach US$ 27,989.14 Million by 2028. This translates to a CAGR of approximately 3.9% during the forecast period.
The North America Metastatic Cancer Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Metastatic Cancer Drugs Market report:
The North America Metastatic Cancer Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Metastatic Cancer Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Metastatic Cancer Drugs Market value chain can benefit from the information contained in a comprehensive market report.